<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02714608</url>
  </required_header>
  <id_info>
    <org_study_id>TCM0319</org_study_id>
    <nct_id>NCT02714608</nct_id>
  </id_info>
  <brief_title>A Study of Ginsenoside H Dripping Pills for Advanced Non-Small Cell Lung Cancer (NSCLC)</brief_title>
  <official_title>A PhaseⅡa, Placebo Parallel Control, Central Randomized, Double Blind, Dosage Exploring and Multi-Center Study to Evaluate the Efficacy and Safety of Ginsenoside H Dripping Pills in Patients With Advanced NSCLC (Syndrome Of Qi-Deficiency)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tasly Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tasly Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ginsenoside H dripping pills is a kind of traditional Chinese medicine(TCM), This study is
      being conducted to evaluate the efficacy and safety of ginsenoside H dripping pills in
      patients with advanced (stage ⅢB/Ⅳ) Non-small Cell Lung Cancer (Syndrome Of Qi-Deficiency)
      and explore the optimal dosage
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Evaluate progression free survival (PFS) in the 3 groups : 0 , every 8 weeks and the end of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Evaluate overall survival (OS) in the 3 groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression(TTP)</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Evaluate time to progression(TTP) in the 3 groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>[0 , every 4 weeks and the end of treatment] To determine the quality of life by using the European Organisation of Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) scales.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms scores of TCM</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>0 , every 4 weeks and the end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cancer-related fatigue</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Evaluate the fatigue degree in the 3 groups using the Chinese version of Brief Fatigue Index (BFI-C): 0 , every 4 weeks and the end of treatment</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Blood routine test</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>0 , every 4 weeks during the period of 0 to 16 weeks, every 8 weeks after 16 weeks and the end of treatment</description>
  </other_outcome>
  <other_outcome>
    <measure>Urine routine test</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>0 , every 4 weeks during the period of 0 to 16 weeks, every 8 weeks after 16 weeks and the end of treatment</description>
  </other_outcome>
  <other_outcome>
    <measure>Hepatic function</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>0 , every 4 weeks during the period of 0 to 16 weeks, every 8 weeks after 16 weeks and the end of treatment</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Non-small Cell Lung Cancer (NSCLC)</condition>
  <arm_group>
    <arm_group_label>Ginsenoside H dripping pills</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Ginsenoside H dripping pills. Dosage form:pill. Dosage :20pills ( only ginsenoside H dripping pills). Frequency:two times per day. Duration: until disease progression or death.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ginsenoside H dripping pills+Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Ginsenoside H dripping pills ,Placebo. Dosage form:pill. Dosage :20pills ( ginsenoside H dripping pills 10 pills and placebo 10 pills). Frequency:two times per day. Duration: until disease progression or death.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug: Placebo. Dosage form:pill. Dosage :20pills ( only placebo ). Frequency:two times per day. Duration: until disease progression or death.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ginsenoside H dripping pills</intervention_name>
    <description>Experimental: Ginsenoside H dripping pills. Dosage form:pill. Dosage :20pills ( only ginsenoside H dripping pills). Frequency:two times per day. Duration: until disease progression or death.</description>
    <arm_group_label>Ginsenoside H dripping pills</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ginsenoside H dripping pills+Placebo</intervention_name>
    <description>Experimental: Drug: Ginsenoside H dripping pills+Placebo. Dosage form:pill. Dosage :20pills ( ginsenoside H dripping pills 10 pills and placebo 10 pills). Frequency:two times per day. Duration: until disease progression or death.</description>
    <arm_group_label>Ginsenoside H dripping pills+Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Comparator: Placebo. Dosage form:pill. Dosage :20pills ( only placebo ). Frequency:two times per day. Duration: until disease progression or death.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Pathologically or cytologically proven stage IIIB/IV NSCLC with a measurable lesions
             (including postoperative recurrence or metastasis)

          2. The patients who can not be treated by surgical resection, conventional radiotherapy
             and chemotherapy or molecular targeted drugs treatment failure, not willing to accept,
             or intolerance to radiotherapy and chemotherapy or molecular targeted therapy.

          3. The TCM Syndrome diagnosis of Qi-Deficiency.

          4. Aged 18-75 years, both male and female.

          5. ECOG performance status 0-2.

          6. Expected to survive more than 3 months.

          7. Joined in the test voluntarily and signed the Informed consent by GCP regulation.

        Exclusion Criteria:

          1. Liver and kidney damage(TBIL、ALT、AST is higher than the limit of normal value of 1.5
             times, abnormal Cr).

          2. Patients with significant cachexia.

          3. Untreated symptomatic brain metastases.

        4 .Allergic constitution, or for a variety of drug allergy.

        5 .Combined with severe cardiovascular, hepatic, renal disease , pregnancy or
        breast-feeding women, psychopath.

        6. Participated in other clinical trial within 3 months.

        7. Treated by chemotherapy, radiotherapy or targeted therapy within 4 weeks.

        8. Possible to be treated by chemotherapy, radiotherapy or targeted therapy during the
        study.

        9. Not fit for the clinical trial judged by the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min Zhao, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Tasly Group, Co. Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Min Zhao, PhD</last_name>
    <phone>008613820845180</phone>
    <email>zhaomin@tasly.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ning Dai</last_name>
    <phone>008613612187689</phone>
    <email>daining@tasly.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Guangdong Provincial Hospital of TCM</name>
      <address>
        <city>Guang Zhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wanyin Wu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Guangzhou University of TCM</name>
      <address>
        <city>Guang Zhou</city>
        <state>Guangdong</state>
        <zip>510405</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lizhu Lin</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jiangsu Provincial Hospital of Integrated Chinese Traditional and Western Medicine</name>
      <address>
        <city>Nan Jing</city>
        <state>Jiangsu</state>
        <zip>210028</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shibing Liao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jing'an District Centre Hospital of Shanghai</name>
      <address>
        <city>Shang Hai</city>
        <state>Shanghai</state>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xueyong Wu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shuguang Hospital Affiliated with Shanghai University of TCM</name>
      <address>
        <city>Shang Hai</city>
        <state>Shanghai</state>
        <zip>201203</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qi Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>West China Hospital ,Sichuan University</name>
      <address>
        <city>Cheng Du</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ying Zhang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second People's Hospital of Yibin</name>
      <address>
        <city>Yibin</city>
        <state>Sichuan</state>
        <zip>644000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yuming Jia</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin People's Hospital</name>
      <address>
        <city>Tian Jin</city>
        <state>Tianjin</state>
        <zip>300000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qiang Yao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hangzhou First People's Hospital</name>
      <address>
        <city>Hang Zhou</city>
        <state>Zhejiang</state>
        <zip>310002</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shengyou Lin</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 29, 2016</study_first_submitted>
  <study_first_submitted_qc>March 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2016</study_first_posted>
  <last_update_submitted>March 19, 2017</last_update_submitted>
  <last_update_submitted_qc>March 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

